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ABSTRACT 
CARDIOVASCULAR RISK, REMOTE ISCHEMIC POSTCONDITIONING, AND 
ENDOTHELIAL ISCHEMIA-REPERFUSION INJURY 
BRIAN A. HEMENWAY 
2017 
Remote ischemic postconditioning (rIpost) is a potent vasculoprotective stimulus 
that is thought to reduce reperfusion injury associated with heart disease. However, 
certain animal models of cardiometabolic risk factors such as dyslipidemia, diabetes, and 
hypertension suggest the beneficial effects of rIpost to lessen reperfusion injury may be 
diminished. These findings have not been studied in clinically relevant humans. The aim 
of this study was to determine whether the protective effects of rIpost are reduced in the 
context of raised cardiometabolic risk in humans. 
Seven participants with raised cardiometabolic risk burden (age: 577 years; 
BMI: 314 kgm2) participated in this 2X2 randomized cross-over design study. Raised 
cardiometabolic risk was established by the presence of 2 or more major risk factors and 
a 10-year Framingham risk score ≥10%. Microvascular endothelial function was 
measured using peripheral arterial tonometry (EndoPAT 2000, Itamar Medical Inc.) 
before and after 20 minutes of left arm, brachial artery ischemia, with and without the 
induction of rIpost (three, 5-minute bouts of right arm ischemia and reperfusion at 220 
mmHg). Remote Ipost procedures were initiated immediately at the onset of reperfusion 
injury. Microvascular endothelial function was also assessed during a sham trial 
consisting of mock occlusions at the brachial artery (three, 5-minute inflations at  
20 mmHg).  
 
 
ix 
Five of the seven participants completed both the sham and rIpost trials. In these 
individuals, the reactive hyperemia index (RHI) at baseline during the sham trial was 
1.260.36 and increased 38% following endothelial injury to 1.740.23 (p=0.108). 
Similarly, the RHI increased 24% from 1.350.46 to 1.670.4 (p=0.358) during the rIpost 
trial. Reactive hyperemia index following endothelial injury at 30-second intervals was 
also not affected by rIpost (p=0.27). There was a trend for the rIpost response following 
endothelial injury to be inversely related to the total number of risk factors (R2=0.53, 
p=0.04) 10-year Framingham risk score (R2=0.27, p=0.19), and the ACC/AHA ASCVD 
risk score (R2=0.30, p=0.16), particularly during the most potent window of reactive 
hyperemia. 
The ability of rIpost to reduce microvascular endothelial injury was not different 
compared with the sham trial, but tended to be worse in participants with elevated 
cardiometabolic risk factors.  
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INTRODUCTION 
Microvascular reperfusion injury is the inevitable result following an extended 
period of ischemia occurring within an organ or tissue. Upon prolonged occlusion, the 
tissue deprived of direct blood supply eventually experiences necrosis, or infarct. The 
infarct may begin to develop after only 30 minutes of restricted blood flow, and the 
reintroduction of oxygenated blood to the site of damage causes the infarct size to grow 
even larger; a phenomenon referred to as ischemia-reperfusion (IR) injury. 1 Reperfusion 
injury not only increases an individual’s chance of re-hospitalization, but also increases 
their risk of mortality. Although there still remains speculation of each specific 
mechanism occurring during IR-injury, it is understood that a rapid ionic shift and pH 
fluctuation serve as the main culprit. The ischemic phase causes a build-up of hydrogen 
ions coupled with ATP depletion, while the reperfusion itself worsens cell function by 
increasing oxidative stress, activating neutrophil accumulation, and stimulating 
inflammatory cytokines, which collectively impair mitochondrial function. 2-5 
Reperfusion injury is of great concern as a decline of active lifestyles coupled 
with unhealthy diets have taken a drastic toll on cardiovascular health, overall resulting in 
increased heart surgeries to treat acute myocardial infarctions. 6-8 Due to an increased 
prevalence of patients at high risk, coronary revascularization surgeries have become 
more complicated over the years resulting in an increased incidence of surgical and post-
operative complications. 9 The most common forms of cardiovascular surgeries that result 
in IR-injury consist of acute ST-elevation myocardial infarction (STEMI), coronary 
artery bypass grafting (CABG), and percutaneous transluminal coronary angioplasty 
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(PTCA). Currently, IR-injury is untreatable; however, there are many clinical trials of 
cardioprotective strategies to help limit the harm caused by IR-injury.  
Ischemic conditioning is the most powerful cardioprotective strategy identified to 
date. Ischemic conditioning consists of interspersed bouts of ischemia and reperfusion 
that are mild enough in duration and frequency to avoid damaging tissues. This 
methodology of cardioprotection triggers a hormetic response that may potentially reduce 
the overall extent of IR-injury, along with stimulating protection in all major organs and 
tissues including the heart, brain, kidneys, lungs, and skeletal muscle. The three main 
types of ischemic conditioning are: pre- (conditioning prior to ischemic injury), per- 
(conditioning during ischemic injury), and post- (conditioning after ischemic injury). 
These strategies are currently being investigated in several small clinical trials to 
determine if they can reduce cellular injury caused by ischemia and reperfusion. Pre- and 
perconditioning, although proven very efficacious, are less practical as we are unable to 
predict when an ischemic injury-causing event will occur, and thus unable to provide 
conditioning in a timely manner. 10 On the other hand, postconditioning has worthy 
therapeutic efficacy as it is implemented at the onset of reperfusion, immediately after 
ischemic episode is cleared, and has shown excellent clinical utility in emergency 
situations. Local postconditioning (occurring at the site of injury), has been shown to 
reduce IR-injury, and overall infarct size when applied during surgeries such as coronary 
angioplasty. 11 Remote conditioning (occurring distal to the site of injury) is typically 
applied on the upper arms or legs, and provides distant-site protection to organs and 
tissues experiencing IR-injury. Despite its practicality and ease of use, remote 
postconditioning has yet to be translated to a widespread clinical setting.  
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Individuals requiring coronary revascularization surgeries are typically plagued 
with a number health risks referred to as cardiovascular disease risk factors. 
Cardiovascular disease (CVD), or a cluster of risk factors including: age, family history, 
smoking, physical inactivity, obesity, hypertension, dyslipidemia, and pre-diabetes, is an 
ever-growing culprit of morbidity and mortality. 12 These risk factors have detrimental 
effects on the vascular system, and increase the likelihood of myocardial infarction, 
stroke, heart failure, and diabetes. An increased prevalence of risk factors reduces the 
benefit of CVD treatments and/or surgeries, and intensifies IR-injury by weakening the 
vascular endothelium. Certain risk factors, such as aging, hyperlipidemia, hypertension, 
and diabetes, have all been shown to reduce the effects of ischemic preconditioning and 
cause greater vulnerability to vascular IR-injury in specific animal models. 13,14 However, 
very limited data are available with respect to the correlation between risk factors and the 
benefit of ischemic postconditioning. Furthermore, these findings have not ascertained in 
humans who have a chronically elevated burden of risk factors, proving an underlying 
issue translating findings from pre-clinical animal models to humans. 15 
 
Statement of Problem 
Remote ischemic postconditioning (rIpost) is a promising experimental strategy 
used to reduce endothelial IR-injury. However, while animal models suggest that CVD 
risk factors may potentially reduce the protective benefits, data in human populations are 
limited. This study aims to provide a base of clinical knowledge of the correlation 
between CVD risk factors and rIpost, deemed advantageous to research and medical 
communities alike.  
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Specific Aim – The purpose of this quantitative experimental research study is to 
determine how cardiovascular risk factors affect the vasculoprotective capacity of rIpost 
and its ability to protect against endothelial IR-injury in humans. 
H0 – An elevated burden of risk factors will exacerbate IR-injury and diminish the 
protective capacity of rIpost in the instance of endothelial IR-injury.  
 
Independent Variable(s) 
 Low burden risk vs. Raised burden risk 
 Experimental (rIpost) protocol vs. Sham protocol 
Dependent Variable(s) 
 Microvascular endothelial vasodilator function (reactive hyperemia) 
 
Delimitations – Due to geographical location, participants will be recruited from 
Brookings County, South Dakota and the immediate surrounding area, allowing for all 
racial and ethnic backgrounds. All recruited participants must be classified as physically 
inactive. Participants may not have CVD or metabolic disease (with the exception of 
diabetes), or history of CVD as classified by the ACSM. 12,16,17 Participants may currently 
be taking medications if they are able to withhold their prescriptions the day of each trial.  
 
Limitations – The greatest limiting factor remains that participants are required to be 
sedentary and free of CVD. Additionally, smooth muscle relaxation is not being 
measured during this study, which should be taken into account when determining the 
reactive hyperemic response.  
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Definition of Terms 
Ischemia-reperfusion injury (IR-injury) – Tissue or vascular injury occurring 
with the sequential act of prolonged ischemia followed by the rapid restoration of 
blood flow, causing cellular/endothelial dysfunction in the form of reperfusion 
arrhythmias, myocardial stunning, and potential necrosis.  
Reactive hyperemia – Provisional over-shoot of blood flow, resulting from an 
excess build-up of vasodilating metabolites during an extended length of 
ischemia, immediately occurring during reperfusion.  
Ischemic conditioning – Tissue/organ and vascular protective mechanism 
resulting from regulated, brief bouts of ischemia and reperfusion that stimulate 
cellular protection pathways, which have the potential to limit and/or reduce the 
prevalence of cellular dysfunction, infarct size, and necrosis.  
Remote ischemic postconditioning (rIpost) – Ischemic conditioning applied 
remotely (distal to the target organ), immediately at the onset of reperfusion 
within the previously ischemic organ or tissue.  
Vascular endothelium – The innermost monolayer of a blood vessel in direct 
contact with blood itself, modulating the secretion of vasodilating, 
vasoconstricting, and anti-thrombogenic factors. Thus, the vessel’s ability to 
vasodilate and constrict proves a reliable measure of endothelial function.   
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REVIEW OF LITERATURE 
The following review of literature will attempt to provide an in-depth synopsis of 
IR-injury (focusing on the endothelium and myocardium), mechanisms/cell biology of 
damage-causing events during ischemia and reperfusion, and protection afforded by 
ischemic conditioning through its ability to combat reperfusion injury. Current clinical 
trials in animals and humans will be reviewed, while taking into account cardiometabolic 
risk, and providing insight toward clinical implications and/or complications of 
implementing rIpost with humans presenting a cluster of risk factors. 
 
Clinical Relevance of IR-Injury 
During an ischemic event, such as a heart attack or stroke, the transport of blood 
is blocked as some form of occlusion (e.g., plaque) prevents normal continual blood flow. 
Without constant blood flow, the tissue beyond the blockage will quickly become 
deprived of oxygen and nutrients, which begins the cascade of adverse events throughout 
the body. Eventually, if ischemia is prolonged beyond 15 minutes, the tissue will begin to 
die and the organ experiences necrosis. The site of necrosis may also be referred to as 
infarct, referencing the specific location and size of dead tissue within the organ 
(immediate hypoxic tissue) and its surrounding area. Certain biomarkers such as lactate 
dehydrogenase, creatine kinase-MB, and cardiac troponin and are often used to assess 
this type of myocardial damage. Researchers have indicated that these biomarkers are 
naturally elevated during cardiac revascularization surgeries, and are exacerbated in high-
risk patients suffering extensive IR-injury. 18,19 Originally it had been believed that the 
sole cause of tissue damage resulting from an ischemic event was simply due to ischemia, 
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or lack of oxygen; however, it has since been recognized that reperfusion also induces 
supplementary damage and can further intensify infarct size. 20,21 Reperfusion, while vital 
for survival, poses a major drawback by stimulating damage severe enough to expand the 
original infarct size upwards of 50-percent of the post-ischemic size. 22 If severe enough, 
reperfusion injury may even lead to remote damage in other organs and tissues within the 
body that were never initially subjected to ischemia. Additional damage to the vascular 
endothelium resulting from IR-injury reduces its capacity of vasocontrol in the form of 
blunting endothelial-derived relaxing factors, nutrient delivery, and elimination of 
harmful waste. 23 Though it is most detrimental within the heart, many other organs, such 
as the brain, lungs, intestines, kidneys, and skeletal muscle are also largely affected by 
IR-injury.  
Ischemia-reperfusion injury continues to prevail as the culprit of a paradoxical 
dilemma where that which is necessary for survival comes at the cost of compromising 
other organs and tissues. The mechanisms have been thoroughly studied through the 
clinical induction of IR-injury using many animal models. The instance of injury occurs 
locally, where stroke victims, for example, experience neuronal damage through cerebral 
ischemic injury followed by rapid reperfusion, altogether compromising the permeability 
of the blood-brain barrier and promoting harmful leakage. 24 However, IR-injury may 
also be remotely transferred throughout the body, which has been demonstrated in 
clinical situations such as pulmonary transplantation, where blood-free surgical 
procedures expose a patient to IR-injury, directly leading toward graft dysfunction and a 
decreased rate of survival. 25  
 
 
8 
An array of pre-clinical studies have demonstrated the detriment of IR-injury in 
lungs, myocardial tissue, endothelial cells, skeletal muscle, and more. While assessing 
protective strategies against pulmonary IR-injury in rat models, Dorsa and colleagues 
(2015) noted extensive damage to the lungs after 30 minutes of occlusion at the 
abdominal aortic artery, followed by 60 minutes of reperfusion. 26 The remote IR-injury 
led to moderate-to-severe edema in the alveolar septa, as well as moderate congestion, 
and excessive neutrophil accumulation. 26,27 Similarly, Hirano et al., (2016) triggered 
remote IR-injury in the lungs of mice after after occluding the superior mesenteric artery 
for 45 minutes. Ensuing reperfusion, injury quickly transferred to acute respiratory 
distress syndrome within the following 4 hours. 28 With aims of studying ischemic 
conditioning models on myocardial and endothelial IR-injury, Zhao and colleagues 
(2003) occluded the left anterior descending artery of canine myocardium for 60 minutes, 
followed by 3 hours of reperfusion. Locally, they noted that approximately 25% of left 
ventricular mass was subjected to risk of injury, in which nearly the entire mass 
experienced necrosis. It was noted that both creatine kinase activity as well as 
subendocardial tissue edema drastically increased following reperfusion. Endothelial 
dysfunction was determined through the increased activity of myeloperoxidase and 
polymorphonuclear neutrophil (PMN) accumulation, as well as a blunted vaso-relaxation 
response to acetylcholine. 29 In this instance, both myocardial and endothelial injury 
mimic that which is expected from cardiac revascularization surgeries. In similar surgical 
settings, researchers continue to battle with renal IR-injury and attempt to alleviate harm 
caused from hepatic transplantation and other renal issues causing acute kidney injury 
and increased likelihood of prolonged hospitalization. 30,31  
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As opposed to the aforementioned organs, skeletal muscle can endure much 
longer episodes of ischemia before permanent damage is initiated. Pottecher and 
colleagues (2016) assessed local skeletal muscle IR-injury in the gastrocnemius muscle 
of aged Wistar rats after exposing them to 3 hours of ischemia followed by 2 hours of 
reperfusion. 32 Rats experienced a significant reduction in maximal mitochondrial 
oxidative capacity, along with a drastic decrease in calcium retention capacity, which was 
used as an indicator of apoptosis and early mitochondrial failure. Wang and colleagues 
(2016) observed skeletal muscle IR-injury by subjecting rats to 3 hours of bilateral 
ischemia followed by 6 hours of reperfusion in hind limbs. 33 At the local site of IR-
injury within the gastrocnemius, they noted skeletal muscle degeneration, necrosis, 
interstitial vessel hemorrhaging, and edema. It was conferred that injury remotely 
transferred to the lungs, showing capillary congestion from neutrophil penetration, ruined 
alveolar structures, and interstitial edema.  
However, IR-injury most commonly affects the heart as a primary outcome from 
surgeries performed on patients suffering from coronary heart disease, such as STEMI, 
CABG, percutaneous coronary intervention (PCI), and others using thrombotic drugs. 
These interventions, while essential in reestablishing coronary blood flow to ischemic 
myocardial tissue, have become much more complicated as patients suffer from a cluster 
of cardiometabolic risk factors that reduce procedure effectiveness. 9 Patients suffering 
CABG induced IR-injury are more likely to endure re-hospitalization and premature 
mortality if they present with diabetes, obesity, and/or metabolic syndrome.  
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Clinical Repercussions of IR-Injury 
Extreme benefits of reperfusion are quickly diminished through injury by induced 
clinical barriers such as myocardial stunning, reperfusion arrhythmias, cardiac and/or 
endothelial dysfunction, and no-reflow complications. 22 Cellular necrosis and apoptosis 
are very common during the reperfusion phase following prolonged ischemia. Ischemia-
reperfusion injury may become lethal if the damage is severe enough, or the events are 
too accelerated for the body to withstand.   
Myocardial Stunning 
While myocardial stunning is generally a temporary issue resulting from IR-
injury, it is the first of many complications. Following ischemia, myocardial stunning is 
known to diminish the contractile properties of the immediately reperfused cells, which 
stuns and impairs left ventricular ejection fraction. This has been known to occur 
following 5-15 minutes of ischemia. 34 The decreased responsiveness among the stunned 
cells derives from ATP depletion during ischemia, rapid alteration of metabolites, and 
increased cytotoxic injury of reactive oxygen species (ROS), further discussed in 
mechanisms of IR-injury. Fortunately, myocardial stunning is reversible and occurs in the 
absence of cell death. It has been postulated that myocardial stunning may actually act as 
a protective mechanism allowing the cells to withstand greater a fluctuation of oxygen 
and nutrient delivery. 35   
Reperfusion Arrhythmias  
Following ischemia, the heart may be subject to rapid, irregular rhythms referred 
to as reperfusion arrhythmias. A study performed by Yamazaki and colleagues (1986) 
demonstrated that the occurrence of reperfusion arrhythmias in canine myocardium was 
 
 
11 
significantly greater when the occlusion was abruptly cleared, as opposed to staged 
reperfusion which allowed partial intracoronary reflow for two hours following  
ischemia. 36 Reperfusion arrhythmias are often observed after thrombolytic therapy and 
cardiac surgery, and may occur after only 15-20 minutes of myocardial ischemia, but are 
most often considered clinically non-significant. 34,37 Due to oxygen-derived free radicals 
(ROS) and rapid alteration in intracellular ionic/metabolite concentrations (specifically 
Ca2+ overload), the myocardial cells experience a great variability in electrical activity 
and electrophysiological changes. 36,37 Irregular electrical activity within the cardiac 
muscle is known to lead toward ventricular fibrillation and even ventricular tachycardia.   
Cardiac and Endothelial (Dys)function 
The body’s ability to efficiently maintain vascular tone, regulate inflammation 
and clotting agents, and control substances passed through to the surrounding layers is 
referred to as endothelial function. The endothelium, being the immediate vessel layer 
located in contact with the blood, is primarily responsible for producing and releasing 
vasoactive and anti-thrombogenic substances that preserve vasodilator capacity and 
control constriction. A healthy endothelium is extremely plastic and flexible, responding 
quickly and efficiently to signaling molecules traveling throughout the blood. Being 
culprit of many elements, the endothelium’s vasocontrol diminishes drastically over time. 
Endothelial dysfunction consists of increased endothelial permeability, decreased 
vasodilating properties, increased vasoconstriction, and subsequent loss of control. 
Cardiovascular disease risk factors are directly related to blood vessel health, as the 
greater burden or risk factors trends toward a higher prevalence of endothelial 
dysfunction, atherosclerosis, and atherothrombotic events. 38-40 More specifically, risk 
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factors, such as obesity, are known to preserve nitric oxide synthesis and impair 
vasodilator function. 41 According to Cai and Harrison (2000), there is a positive 
correlation between risk factors and increased oxidative stress in the form of an increased 
prevalence of ROS. 42 Through the increased production of ROS, the bioavailability of 
nitric oxide, arguably the most potent vasodilator, rapidly declines and begins a vicious 
cycle further enhancing dysfunction.  
No-reflow Phenomenon  
Reperfusion following prolonged ischemia (>20 minutes) may cause 
microvascular damage severe enough to prevent continual blood flow to the affected 
area. This is not an issue for myocytes and/or tissues that have already experienced 
necrosis, but could indeed threaten areas experiencing myocardial stunning, which are 
reliant upon blood flow for restoration, thus pushing them to the extent of necrosis. 34 No-
reflow is the undesirable outcome of severe platelet-leukocyte coagulation, increased 
interstitial fluid, and prolonged vasoconstriction. 37 While an acidic environment causes 
leukocytes to become more rigid, they accumulate within the vessel lumen and form a 
blockade. The increased interstitial fluid causes additional pressure pushing inward on the 
vessel walls, eventually causing a collapse of the vessels structure. 35 Not only will this 
phenomenon jeopardize myocytes experiencing myocardial stunning, but will further 
exacerbate the myocardial stunning by prolonging microvascular ischemia.  
 
Mechanisms of IR-Injury 
Ischemia-reperfusion injury has been extensively studied providing a solid 
foundation of interaction between the two phases of injury. Many abnormalities occur 
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within the cell and throughout the surrounding area during both phases of ischemia and 
reperfusion. To date, researchers have pinpointed key mechanisms such as a rapid 
fluctuation of pH, calcium overload, the oxygen paradox, cellular inflammation, and 
mitochondrial dysfunction (Figure 1). 22,35 The culmination of cardiovascular disease risk 
factors further enhances endothelial dysfunction leading to more severe injury that is 
systemically transferred throughout the body to remote organs and tissues. 
Ischemic Induced Anaerobic Metabolism – ATP Depletion 
During ischemia, an inadequate supply of oxygen causes the cells to rapidly 
convert to anaerobic metabolism in a last ditch effort for continued ATP production. As a 
result of decreased ATP production, there is a drastic increase in ADP, AMP, and Pi. The 
lack of blood flow causes a disruption in the transport of glucose and fatty acids, delaying 
the production of pyruvate and Acetyl-CoA, which in turn hinders proper function of the 
Krebs cycle, and ultimately the electron transport chain. If prolonged, the endothelial 
cells and cardiomyocytes will die without a source of viable energy.  
Fluctuation in pH 
Anaerobic metabolism and ATP depletion cause the cells to become extremely 
acidic. During ischemia, the cell initiates a cascade of ionic imbalances with efforts to 
buffer the acidity. The rapid shift to anaerobic metabolism causes the decrease in 
intracellular pH through an overproduction and accumulation of H+. The acidic 
environment is combatted by the excretion of excess H+ into the cytosol through the 
Na+/H+ exchanger, which thus triggers the uptake of residual Na+ into the cell overall 
disrupting the Na+ gradient. 22,35,43 At the onset of reperfusion there is a rapid correction in 
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pH, posing as a source of hypercontracture, along with promoting deleterious effects on 
the mitochondria and a washout of lactic acid into the blood stream. 22 
Calcium Overload  
Calcium overload has been considered one of the main damaging factors during 
both ischemic and reperfusion injury. During ischemia, cellular depletion of ATP causes 
an inhibition of the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA) as well 
as the Na+/Ca2+ exchanger, overall preventing Ca2+ efflux. With reperfusion, Ca2+ 
continues to overload the cell as an accumulation of ROS leads to sarcoplasmic reticulum 
dysfunction, inhibiting the essential up-take of Ca2+. 22 This can be particularly harmful 
due to the activation potential of enzymatic proteases, which may ultimately cause 
hypercontracture and cellular apoptosis. 43,44 The infiltration of macrophages and 
neutrophils cause increased inflammation, damaging the surrounding tissue. The Ca2+ 
continues to overload the mitochondria during the reperfusion phase, leading to the 
detrimental opening of the mitochondrial permeability transition pore (mPTP). 35,45 
Aerobic ATP Production – Oxidative Stress During Reperfusion 
While reperfusion is necessary for the restoration of aerobic metabolism/ATP 
production, it also causes many complications through increased oxidative stress via the 
overwhelming increase in ROS. Key sources of ROS have been identified as xanthine 
oxidase, NADPH oxidase, reenergized mitochondria, lipoxygenase, and nitric oxide 
synthase. The hypoxic stages of ischemia and early reperfusion cause ROS to become 
even more reactive. Increased ROS may lead to the accumulation of procoagulant 
proteins such as tumor necrosis factor (TNF) and transforming growth factor (TGF-). 
The accumulation of ROS has also directly been linked to the alteration and denaturation 
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of lipid membranes and protein structures, along with breaking the strands of 
deoxyribonucleic acid (DNA). This damage may lead to cellular necrosis through the 
opening of the mPTP. 5,46 Damage may also be transferred systemically, promoting the 
adherence of PMN on the endothelial lining of remote organs/tissues. 35 
Opening of the Mitochondrial Permeability Transition Pore (mPTP) 
Located within the mitochondrial inner membrane, the mPTP is activated during 
stressful ischemic events such as myocardial infarction. With great susceptibility, the 
mPTP is forced open during reperfusion via pH correction, Ca2+ overload, and the 
overwhelming accumulation of ROS. Research has pinpointed this protein pore as the 
main culprit of the inhibition of ATP production through the excessive influx of H+ upon 
opening. 35,47 Through the transport of K+ and Pi, the mitochondrial matrix may 
osmotically swell upwards of 20-40% its original size, potentially leading to 
mitochondrial rupture. 35,48 The swelling takes place in an ‘all or none’ manner, where 
mitochondrial Ca2+ overload causes depolarization, overall increasing the mPTP Ca2+ 
sensitivity and triggering a cascade of additional pore openings within the same 
mitochondria. 48,49 Certain cardioprotective strategies, such as ischemic conditioning, aim 
to inhibit the mPTP pore opening, overall eliciting a greater reduction of damage caused 
via IR-injury and preserving the capacity of ATP production.  
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Figure 1. Representation of biomolecular changes occurring during IR-injury in the 
cardiomyocyte and endothelial cells as discussed in Mechanisms of IR-Injury. Image 
modified from Yellon & Hausenloy (2007). 22 
 
 
Ischemic Conditioning 
Ischemic conditioning activates a hormetic response through short regulated bouts 
of ischemia and reperfusion, used to protect tissues/organs and the vascular system by 
stimulating cellular protection programs aimed at reducing cell dysfunction, infarct size, 
and necrosis. As previously mentioned, there are three different times to administer 
ischemic conditioning: pre- (prior to an event), per- (during an event), and post- (after an 
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event, at the onset of reperfusion). All three types of ischemic conditioning may be 
applied either locally (at the site of the organ or tissue experiencing IR-injury) or 
remotely (distal from the organ or tissue experiencing IR-injury). The foundation of 
ischemic conditioning relies on promoting a reactive hyperemic response, where short 
bouts of ischemia cause a build up of vasodilating metabolites, followed by an overshoot 
of blood flow at the moment of reperfusion. When repeated multiple times, the 
tissue/organ is able to trigger a protective response, which is transferred through the 
vascular system throughout the body. There has yet to be a standardized protocol for any 
form of ischemic conditioning, but the trend in literature typically consists of three, 5-
minute bouts of ischemia followed by 5-minute bouts of reperfusion (3X5), or four, 3-
minute bouts of ischemia followed by 3-minute bouts of reperfusion (4X3). All forms of 
ischemic conditioning provide two windows of protection. 50 An early phase, or classic 
phase, of protection begins only minutes after the completion of ischemic conditioning, 
lasting approximately 2 to 4 hours. 50,51 Although the early phase of protection is short-
lived, it is very potent and has been linked with a great degree of infarct size reduction. A 
second window of protection (SWOP) occurs between 12 and 72 hours after ischemic 
conditioning, greatly expanding the overall length of protection, but occurring with a 
lower degree of infarct size reduction. 50,52,53   
 
Protective Effects of rIpost 
Particular cardioprotective strategies have been adapted in efforts of reducing the 
detriment caused via IR-injury. Ischemic postconditioning, being one of the more 
practical methods, eliminates the dilemma of predicting the exact moment of an ischemic 
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event as it is applied immediately at the onset of reperfusion following the prolonged 
ischemia. Remotely applied distal from the compromised organ, rIpost is a simple, non-
invasive method of cardioprotection that shows great clinical therapeutic efficacy.  
Mechanisms of Ischemic Postconditioning to Improve Endothelial Function 
Endothelial dysfunction, resulting from IR-injury, proves to be one of the most 
detrimental factors for the body to overcome. As the endothelium is responsible for 
vascular tone and remodeling, endothelial dysfunction has been directly related to a more 
severe degree of infarction. 54 Remote Ipost has been shown to attenuate endothelial 
dysfunction through both neural and humoral influences (Figure 2). The neural theory 
begins with the activation of G-protein coupled receptors, which are known to initiate the 
action of intracellular signaling pathways. 55 At this time, the activation of adenosine, 
bradykinin, and opioid receptors stimulate the process of amplified vasodilation, and 
trigger the humoral pathway. The humoral action activates downstream signaling 
cascades of phosphatidylinositol 3-kinase (PI3K), protein kinase, and extracellular signal-
related kinase1/2 (ERK1/2), to be transferred throughout the body. Remote Ipost has also 
been shown to aid in the slowed restoration of pH, which was subsequently lowered 
during the ischemic phase of IR-injury. Research indicates rIpost has the potential to 
reduce infarct size approximately 36% when compared to a control group. 11   
The two key pathways that have been directly linked to cardioprotection resulting 
from rIpost are the reperfusion injury salvage kinase (RISK) and survivor activating 
factor enhancement (SAFE). The RISK pathway, activated by ROS and protein kinase C, 
activates PI3K, an enzyme involved in many cellular functions such as cell survival and 
intercellular trafficking, and ERK1/2, which is a protein kinase involved in meiosis and 
 
 
19 
mitosis. Together, PI3K and ERK1/2 phosphorylate downstream targets such as glycogen 
synthase kinase-3 (GSK-3), which ultimately deters the opening of the mPTP. 56 The 
SAFE pathway is initiated by increased levels of TNF during the ischemic phase, which 
transphosphorylates adjacent Janus kinase (JAK) allowing it to transduce signals from the 
cell cytosol to the nucleus, ultimately activating the signal transducer and activator of 
transcription (STAT-3) pathway. 56 It has been suggested the RISK and SAFE pathways 
have some form of cross communication, and if either pathway is not activated during 
conditioning, cardioprotection will be diminished. 57,58 With the end goal of preventing 
the mPTP from opening, rIpost preserves mitochondrial function and allows cellular 
aerobic metabolism to proceed. 
 
 
Figure 2. Mechanistic flowchart of remote ischemic pre- and postconditioning from the 
application of conditioning stimuli to the post-translational modification of end-effectors. 
Image modified from Krenz et al., (2013). 43 
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CVD Risk Factors and Ischemic Conditioning 
Many animal models, and few human studies, have been conducted over the years 
looking for a correlation between the incidence of cardiometabolic risk factors and the 
perceived benefit from ischemic conditioning. Although most literature documents 
ischemic preconditioning (utilizing very similar mechanisms) on animal models with 
induced risk factors, a trend in the data makes it quite clear that the protective benefit 
may be greatly diminished. One example of the very few human studies compared young 
men (20-25 years) to older men (68-79 years) in efforts of demonstrating the effects of 
advanced age on remote ischemic preconditioning. In this study the conditioning stimuli 
was performed for three, 5-minute cycles, thereafter IR-injury was induced on the 
opposite arm. Using flow mediated dilation of the brachial artery, researchers noted that 
endothelial function in older subjects decreased nearly twice the extent of that seen in 
younger subjects, and showed a much longer time to full restoration. Researchers 
concluded that advanced age eliminated the ability of ischemic preconditioning to 
attenuate endothelial dysfunction. 14 This particular study serves as a nice foundation and 
first step in linking risk factors with the reduced benefit of conditioning in humans. 
With regards to ischemic postconditioning, select studies have assessed risk 
factors such as diabetes mellitus, hypertension, and hypercholesterolemia. Utilizing 
clinically induced diabetic Wistar rats, efficacy of postconditioning has been assessed 
through changes in infarct size. Badalzadeh et al., (2015) determined the infarct size of 
the diabetic rat hearts was completely unaffected by their postconditioning treatment 
when compared to the healthy control group. Researchers explain that the diabetic state 
further increases oxidative stress, thereby inactivating the RISK pathway, and more 
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specifically the ability to phosphorylate GSK-3, which further enhances cell damage by 
allowing the active protein kinase to induce apoptosis. 59 A very similar mechanism was 
also reported in spontaneously hypertensive rats by Wagner and colleagues (2013). Two 
different postconditioning methods were implemented in two groups of rats subjected to 
either 20 or 30 minutes of ischemia. 60 The results concluded that myocardial 
hypertrophy, cardiac remodeling resulting from the overload of spontaneous 
hypertension, hindered the capacity of cardioprotection. Like the previous study with 
diabetes, these researchers suggested that hypertension prevented the phosphorylation of 
GSK-3, whereas the non-hypertensive control group experienced a 2.1 fold increase in 
the phosphorylation of GSK-3, which aided in preventing the opening of the mPTP. 60 
Additionally, in the case of clinically induced hypercholesterolemic male Wistar rats, Wu 
and colleagues (2015) also reported no perceived cardioprotection from rIpost. 61 These 
specific rats were fed a cholesterol rich diet for 8-weeks, at which point IR-injury was 
induced and rIpost was completed. Researchers concluded that hypercholesterolemia 
inactivated the RISK pathway by blocking the phosphorylation of protein kinase B (Akt) 
and ERK1/2, overall abolishing the effects of rIpost. 61 While these pre-clinical trials 
demonstrate a large disconnect between cardioprotective ischemic conditioning and 
cardiometabolic risk factors, the literature lacks necessary evidence in human models.  
 
Transferring Data to Human, Clinical Applications 
The most drastic IR-injury occurs in individuals with a cluster of cardiometabolic 
risk factors as the endothelium is already compromised prior to the ischemic event. The 
previously discussed animal models had only utilized one acute, clinically-induced risk 
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factor per study as opposed to a more realistic cluster of risk factors expected in a human 
sample. Due largely in part to the Western diet being greatly over-proportioned and high 
in fat and sugar, along with increased physical inactivity, the prevalence of 
cardiometabolic risk factors are vastly increasing. 6,7 The unfortunate truth is that the 
patients who will most likely require some form of cardioprotection are the ones who 
suffer from significant disease burdens. In the majority of animal models, the induced 
ischemia is caused via an external occlusion of an otherwise healthy artery; whereas in 
real-life situations, humans will experience an internal blockage resulting from an 
unhealthy artery. 15 By way of nature, these risk factors build upon one another over the 
course of decades, making animal models truly non-replicable. To date, no studies have 
observed the effects of ischemic postconditioning on humans with a cluster of risk 
factors. This particular study aims to be the first to observe the response of rIpost in 
individuals suffering from a cluster of cardiometabolic risk factors.  
 
Conclusion 
 Ischemia-reperfusion injury is a detrimental phenomenon that has been culprit of 
severe medical complications for many years. While certain cardioprotective 
mechanisms, such as rIpost, have been studied, there remains a large gap in the literature 
preventing researchers from translating data to real-life scenarios. Individuals plagued 
with multiple CVD risk factors are ultimately the ones who will be treated for cardiac-
related events and subjected to IR-injury. In order to successfully implement ischemic 
conditioning into a clinical setting, we must better understand its underlying relation with 
CVD risk factors.   
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MATERIAL AND METHODS 
The present study was completed at the Vascular Protection Research Laboratory 
through the College of Education and Human Sciences at South Dakota State University. 
Research had been approved by the Institutional Review Board #IRB-1507003-EXP.  
 
Specific Aim – This quantitative experimental research study aimed to determine the 
effects of CVD risk factors on the ability of rIpost to protect against endothelial IR-injury 
in humans. With reference to the literature previously cited, it is hypothesized that an 
elevated burden of CVD risk factors will further the damage of endothelial IR-injury and 
greatly reduce the potential benefit of rIpost.  
 
Participant Eligibility Screening – Ten participants (8 males; ages 23-66 years) 
enrolled in the study, having been recruited via flyers and letters of invitation 
(Appendices A & B). One participant had withdrawn from the study prior to the first 
session for unaffiliated reasons. Eligible participants were thoroughly explained each 
procedure and any potential risk as listed on the informed consent (Appendix C). Prior to 
the first session, each participant completed a ‘PAR-Q & You’ health history 
questionnaire (Appendix D) providing pertinent medical information. During the first 
session, baseline measurements were collected for use of determining each individual’s 
CVD risk classification (Appendices E-H). 
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 Inclusion Criteria 
 Men and women, ages 20 - 79 years 
 All races and ethnicities  
 Physically inactive – Less than 30 minutes of physical activity 3 daysweek-1 
for the past 3 months 
 No history of cardiovascular, pulmonary, and/or metabolic disease  
(exception of diabetes; n=1) 
 Non-smoking 
 
Exclusion Criteria 
 Physically active – Achieving a minimum of 30 minutes of physical activity 3 
daysweek-1 for the past 3 months 
 Known cardiovascular, pulmonary, and/or metabolic disease  
(exception of diabetes; n=1) 
 Smoking, or having quit smoking in the past 6 months  
 
Identification of the Burden of Cardiometabolic Risk 
Cardiometabolic risk was assessed using the American Heart Association’s risk 
classification of participants’ current health and family history as recommended by the 
American College of Sports Medicine. 12,62 Participants were classified into either a raised 
burden group (2 risk factors and FRS 10%) or a low burden group (<2 risk factors) 
using the following guidelines: 
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 Age – Men 45 years of age & women 55 years of age 
 Family History – Myocardial infarction, coronary revascularization, or sudden 
death before 55 years in father or other first-degree male relative, or 65 years 
in mother or other first-degree female relative 
 Physically Inactive – Not having participated in a minimum of 30 minutes of 
moderate intensity physical activity at least 3 daysweek-1 for the past 30 days  
 Obesity – BMI 30 kgm2 or waist circumference >102 cm for men and  
>88 cm for women 
 Hypertension – Systolic blood pressure 140 mmHg and/or diastolic blood 
pressure 90 mmHg 
 Dyslipidemia –  
o LDL-cholesterol 3.36 mmolL-1  
o HDL-cholesterol <1.03 mmolL-1  
(Negative risk factor if HDL 1.55 mmolL-1) 
o Total cholesterol 5.17 mmolL-1 
 Prediabetes – Impaired fasting blood glucose 5.56 mmolL-1 
 
Baseline Measurements and CVD Risk Stratification 
Anthropometric and Baseline Measurements 
Auscultatory resting systolic and diastolic blood pressure and pulse rate were 
assessed using a GE Healthcare Carescape V100 monitor (GE Healthcare., Chicago, IL, 
USA) following 5 minutes of seated quiet rest. Body mass was measured to the nearest 
0.1 kg using the Cosmed BOD POD integrated digital scale, and percent body fat was 
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assessed using air displacement plethysmography (BOD POD, Cosmed USA Inc., 
Chicago, IL, USA). Body mass index (BMI) was calculated as weight (kg) divided by 
height (m) squared. Abdominal obesity was measured to the nearest 0.1 cm using the 
circumference at the narrowest region of the abdomen between the peak of the iliac crest 
and xiphoid process. Hip obesity was measured at the greatest circumference of the 
buttocks – both measurements taken while participants were standing erect with feet 
together. Participants completed an 8-minute Ebbeling walk test to assess their level of 
cardiorespiratory fitness with a predicted VO2max (Appendix H).  
Metabolic Measurements  
Following an overnight fast, a 40L sample of blood was collected from the index 
finger using a 21 G, 0.81 mm Fisherbrand lancet and capillary tube. Samples were 
analyzed using an Alere Cholestech LDX analyzer (Alere Inc., Waltham, MA, USA), 
assessing a full lipid profile consisting of total cholesterol, LDL-cholesterol, HDL-
cholesterol, triglycerides, and impaired fasting blood glucose.  
CVD Risk Stratification 
 Thorough analysis of each PAR-Q document, as well as anthropometric and 
metabolic measurements provided the necessary information to quantify absolute number 
of risk factors. Participants were given one positive risk factor with reference to each 
criteria they met in the guidelines listed above. A negative risk factor was given for those 
who exceeded the guidelines for HDL-cholesterol. Online Framingham risk score (FRS) 
and ACC/AHA ASCVD risk calculators were used to assess the participant’s likelihood 
of developing CVD in the next 10-years.  
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Experimental Design 
A 2X2 randomized cross-over design was used to assess two independent 
variables. The first of which was risk burden, where participants were classified into 
either a low- or raised-burden group. The second independent variable served as the 
randomization of the order they received the sham (20 mmHg) and rIpost (220 mmHg) 
protocols.  
 
Measurement of Microvascular Endothelial Function 
Endothelial function can be measured multiple different ways among many 
different capillary beds. The two preferred methods of measurement are by determining 
vasorelaxing/dilating properties of an artery or capillary bed when prompted with 
pharmacological or flow-mediated vasodilation (reactive hyperemia). For the purpose of 
measuring endothelial function using reactive hyperemia as the stimulus, the brachial and 
conduit arteries and finger microvasculature are typically utilized. Using finger 
plethysmography has become more popular as the arm opposite of the stimulus (reactive 
hyperemia) may be used as a control. 63 Endothelial dysfunction was measured using a 
non-invasive, FDA-approved technology known as EndoPAT (pulse arterial tonometry), 
which utilizes fingertip sensors that measure changes in microvascular pressure created 
from arterial blood volume (EndoPAT 2000, Itamar Medica Inc., Caesarea, Israel).  
During Phase 1, the participants lay supine in a bed while fingertip sensors were 
placed on each index finger, making sure the tip of the finger reached the back of the 
sensor. Each sensor would inflate to 10 mmHg below the individual’s diastolic blood 
pressure, which was manually entered into the program. After 5 minutes of recording 
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baseline data of microvascular function, a rapid-inflation blood pressure cuff (Hokanson 
AG101/E20, D. E. Hokanson Inc., Bellevue, WA, USA) placed on the upper left arm was 
inflated to 220 mmHg for 5 minutes, occluding blood flow beyond the site of the cuff. 
The blood pressure cuff was the deflated following the 5 minutes of forearm occlusion, 
where an additional 5 minutes of data were collected to assess reactive hyperemia.  
 
Figure 3. Representative tracing of baseline, occlusion, and reactive hyperemic phases 
measured in a low risk burden participant using PAT to assess microvascular endothelial 
function. Each block represents a 5-minute increment.  
 
 
The total baseline assessment of microvascular endothelial function lasted approximately 
15 minutes. Following baseline assessment, a 15-minute washout period was 
implemented, where participants were free to stand up and move around allowing the 
body to return to homeostasis prior to the induction of IR-injury and rIpost/sham.  
  Beginning Phase 2, participants were instructed to lay supine in a bed while a 
rapid-inflation blood pressure cuff on the upper left arm was inflated at 220 mmHg for 20 
consecutive minutes. Immediately at the onset of left arm reperfusion, either an rIpost 
(220 mmHg) or sham (20 mmHg) protocol was implemented on the right arm consisting 
of a regulated cycle of three, 5-minute bouts of ischemia/reperfusion. Remote Ipost 
procedure was completed according to common protocols cited in the 2015 meta-analysis 
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from Le Page and colleagues. 64 Following the last 5-minute reperfusion period of 
rIpost/sham, Phase 3 was implemented to measure the reactive hyperemic response of the 
experimental protocols, mirroring the identical processes of Phase 1, while using new 
fingertip sensors (Figures 3 & 4; Appendix I).  
 
Figure 4. Representation of the rIpost (220 mmHg) and sham (20 mmHg) protocols. 
Endothelial function was measured using EndoPAT 2000. 
 
 
Statistical Analysis 
Data was analyzed using IBM SPSS Statistics Version 23.0 (Armonk, NY: IBM 
Corp). Reactive hyperemia index was calculated manually using EndoPAT 2000 
software, as the ratio of reactive hyperemia post- IR-injury to pre- IR-injury of the 
occluded arm relative to the control arm. One-way ANOVA was used to determine 
significance in participant characteristics. Paired samples T-tests were run, analyzing 
heart rate and blood pressure over the course of each trial. Repeated measures ANOVA 
was used to determine differences in the RHI at 30-second intervals in the raised burden 
group. Bivariate correlations were used to determine the relationship between risk 
factors, FRS, ACC/AHA, and RHI at 90-120 seconds. Statistical significance was set at 
p<0.05, and data represent meanSD unless otherwise noted. Any missing data was not 
used for analysis, although all attempts were made to retrieve missing data prior to 
analysis.  
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RESULTS 
Participant Data 
Ten participants enrolled in the study, however, one dropped out prior to the first 
session leaving us with a sample of nine individuals (7 males, 2 females; ages 23 – 66 
years; 7 raised burden, 2 low burden). The two women (1 raised burden, 1 low burden) in 
the study were both pre-menopausal. Due to the size of the control group (n=2), the low 
burden characteristics will not be listed in a table. However, the two low burden 
participants (1 male, 1 female; age: 3213 years; BMI: 23.50.4 kgm2) were healthy 
individuals with normotensive blood pressure (SBP: 11314 mmHg, DBP: 679 mmHg) 
and very low FRS and ACC/AHA risk scores (2.372.6 % and 0.60.7 %, respectively). 
Of the total sample of nine, only five participants completed both the sham and rIpost 
protocols due to limited supplies, all of whom were classified in the raised burden group. 
Table 1 lists the means and standard deviations of each variable measured for those in the 
raised burden group. 
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Table 1. Sample demographics within the raised burden group. 
Variable 
Raised Risk Burden 
(n=7) 
Age, yrs 577 
Sex, M/F 6/1 
Body Mass, kg 101.117.5 
BMI, kgm2 31.14.4 
Body Fat, % 31.98.9 
Waist Circumference, cm 105.69.7 
Systolic BP, mmHg 12510 
Diastolic BP, mmHg 797 
Total Cholesterol, mmolL-1 5.391.67 
LDL-cholesterol, mmolL-1 3.711.85 
HDL-cholesterol, mmolL-1 1.10.36 
Triglycerides, mmolL-1 1.260.58 
Blood Glucose, mmolL-1 5.630.50 
VO2max, mLkgmin
-1 35.52.91 
10-year Framingham Risk Score, % 18.512.8 
ACC/AHA ASCVD Score, % 10.37.5 
Data represent meanSD. M, male; F, female; BMI, body mass index; BP, blood pressure; 
LDL, low-density lipoprotein; HDL, high-density lipoprotein; VO2max, maximal oxygen 
consumption. ACC/AHA ASCVD, American College of Cardiology/American Heart 
Association Atherosclerotic Cardiovascular Disease.  
 
With an average BMI of 31.14.4 kgm2, the sample was classified obese with a risky 
high level of body fat (31.98.9 %), and excess abdominal obesity with waist 
circumference exceeding 102 cm. An average VO2max of 35.52.91 mLkgmin
-1, 
classified the raised burden group on the “fair/poor” borderline fitness category for 
maximal aerobic power, although two participants were unable to complete the Ebbeling 
walk test due to lower leg injury. 12 This sample was also, on average, classified with 
dyslipidemia and prediabetes, evidenced by elevated levels of total cholesterol, LDL-
cholesterol, and blood glucose. Two participants were currently taking blood pressure 
and diabetes medication, one of whom was also taking cholesterol medication, however, 
every participant withheld all prescriptions/medications the morning of each session.  
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CVD Risk and Overall Burden  
Table 2 depicts the percentage of participants with each specific cardiovascular 
disease risk factor within the two groups. The low burden group exhibited no risk factors, 
while, as expected, the raised burden group were plagued with many. Nearly each raised 
burden participant (86%) received a positive risk factor for age, as well as five of the 
seven (71%) raised burden participants had received a positive risk factor for the 
classification of prediabetes. It is important to note all participants, both low and raised 
burden, were classified as sedentary even though this risk factor is not accounted for in 
Table 2. Participants taking medications for a specific risk factor were classified with that 
risk factor even if the medications maintained their values within normal ranges. 12  
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Table 2. Specific risk factor distribution within each group. 
 
Age  
# (%) 
Family 
History  
# (%) 
Obesity  
# (%) 
Elevated 
BP 
 # (%) 
High Total 
Cholesterol 
# (%) 
High 
LDL  
# (%) 
Low 
HDL  
# (%) 
Elevated 
Triglycerides 
# (%) 
Prediabetes 
# (%) 
Total 
n=9 
 
6 (67) 1 (11) 3 (33) 2 (22) 3 (33) 4 (44) 3 (33) 2 (22) 5 (56) 
Low 
Burden 
n=2 
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Raised 
Burden 
n=7 
6 (86) 1 (14) 3 (43) 2 (29) 3 (43) 4 (57) 3 (43) 2 (29) 5 (71) 
BP, blood pressure; LDL, low-density lipoprotein; HDL, high-density lipoprotein. All participants were classified as sedentary (<30 
minutes of moderate intensity physical activity, 3 daysweek-1 for the past 30 days). 
3
3
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Table 3 shows the distribution of cardiovascular risk factors among the seven 
participants in the raised burden group. The majority of participants (57%) had a total of 
three risk factors, not including sedentary lifestyle. Two participants were classified with 
metabolic syndrome (MetS) according to the definition from The International Diabetes 
Federation. Criteria for MetS includes a BMI 30 kgm2, and/or a waist circumference 
>102 cm for men and >88 cm for women, along with two or more of the following risk 
factors (or current specific treatment): raised triglycerides, reduced HDL-cholesterol, 
raised blood pressure, and raised impaired fasting blood glucose. 65 
 
Table 3. Distribution of cardiovascular risk factors in raised burden population. 
Risk Factors, # Raised Burden Group, # (%) 
0  0 (0) 
1  0 (0) 
2  1 (14) 
3  4 (57) 
4  1 (14) 
5  0 (0) 
6  1 (14) 
Risk factors include age (men 45 yr, women 55 yr); family history (first degree male 
<55 yrs, first degree female <65 yrs suffering from heart disease, prior heart attack, or 
sudden death); BMI 30 kgm2; SBP 140 mmHg; DBP 90 mmHg; elevated total 
cholesterol 5.17 mmolL-1; elevated LDL-cholesterol 3.36 mmolL-1; low HDL-
cholesterol (men <1.03 mmolL-1, women <1.29 mmolL-1); elevated triglycerides 1.69 
mmolL-1; elevated impaired fasting blood glucose 5.56 mmolL-1. Physical inactivity is 
not included in this count. Data represent sum of risk factors (relative %).  
 
Blood Pressure and Heart Rate (sham and rIpost) 
Throughout each session of sham and rIpost, heart rate and blood pressure were 
measured at three different points: baseline (after 5 minutes of quiet rest), immediately 
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preceding left arm IR-injury (30 minutes), and after rIpost/before the final assessment of 
endothelial function (80 minutes) (refer to Figure 4 and Table 4). There was no statistical 
significance in the fluctuation of HR, SBP, and DBP between the three testing points 
within each risk burden group (all p>0.05), however as expected the raised burden group 
showed consistently higher values throughout the course of each trial.  
 
Table 4. Changes in heart rate and blood pressure during the assessment of microvascular 
function with rIpost.  
                                  Low Risk Burden (n=2) Raised Risk Burden (n=7) 
                        Baseline 30 min 80 min Baseline 30 min 80 min 
HR,  
bpm 
557 500 502    608 598 609 
SBP,  
mmHg 
11413 1066 10911    12918 13115 13016 
DBP,  
mmHg 
6611 655 616    737 736 749 
Data represent meanSD. HR, heart rate; SBP, systolic blood pressure; DBP, diastolic 
blood pressure; (all p>0.05). 
 
Assessment of Microvascular Endothelial Function (sham and rIpost) 
 The low burden group only received rIpost, and when comparing the average RHI 
during baseline assessment to the average RHI following IR-injury and rIpost, there were 
no statistically significant changes. Figure 5 shows the RHI, at 30-second intervals, was 
slightly higher in the first 90 seconds following rIpost, however it appears to decline 
more rapidly than the RHI at baseline (all p>0.05).  
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Figure 5. Reactive hyperemia index at 30-second intervals during baseline and following 
IR-injury during the rIpost protocol in the low burden group (n=2; all p>0.05). 
 
With regards to the five raised burden participants who received both sham and 
rIpost protocols, endothelial function, as assessed by the RHI, showed a non-significant 
increase from baseline to post IR-injury in sham (p=0.108) and rIpost (p=0.358) 
(Figure 6).   
 
Figure 6. Change in reactive hyperemia index of the raised burden group (n=5) during the 
sham and rIpost protocols. The sham trial showed a 38.1% increase, while the rIpost trial 
showed a 23.7% increase (all p>0.05). 
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Due to a technical error with the computer program (EndoPAT 2000), we were 
unable to obtain data during the baseline assessment of the rIpost protocol for one raised 
burden participant. Therefore, we were only able to assess RHI at 30-second increments 
for four of the five raised burden participants who receive both the sham and rIpost 
protocols. Figure 7 depicts the average RHI at 30-second intervals during the baseline 
assessment of the sham and rIpost sessions for these four participants. There were no 
statistically significant differences between RHI during the baseline assessment of 
microvascular function in the sham and rIpost sessions (all p>0.05). The percent change 
in RHI from sham to rIpost over the course of the 300 seconds ranged from 12.99% (30 
seconds) to 47% (240 seconds), with an average of 30.57% from 60-300 seconds. 
 
 
Figure 7. Reactive hyperemia index at 30-second intervals before IR-injury (baseline) with 
sham and rIpost trials in four raised burden participants (all p>0.05).  
 
Similarly, the average RHI at 30-second intervals showed no statistically 
significant difference following 20 minutes of left arm IR-injury in the sham and rIpost 
protocols in these same four raised burden participants (Figure 8). The percent change in 
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RHI after IR-injury from sham to rIpost ranged from 0.93% (30 seconds) to 17.86% (180 
seconds), with an average of 11.74% from 120-300 seconds.  
 
 
Figure 8. Reactive hyperemia index at 30-second intervals after IR-injury with sham and 
rIpost trials in four raised burden participants (all p>0.05).  
 
 
CVD Risk and RHI at 90-120 Seconds of Hyperemia  
 
When analyzing the reactive hyperemia index during the most potent time frame 
following rIpost, we observed an inverse relationship between the absolute number of 
risk factors. 66 As shown in Figure 9, data represent a strong negative correlation between 
peak reactive hyperemia and absolute number of risk factors (Figure 9-A, 90 seconds of 
hyperemia, p=0.04), as well as a negative correlation near statistical significance between 
RHI at 120 seconds of hyperemia and absolute number of risk factors (Figure 9-B, 
p=0.061). This data suggests that the greater number of risk factors is associated with a 
blunted reactive hyperemic capacity, despite attempts to induce rIpost.  
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Figure 9. Correlations between total number of risk factors and (A) peak reactive 
hyperemia (90 seconds post-occlusion) and (B) reactive hyperemia at 120 seconds post-
occlusion, both following endothelial IR-injury with rIpost. This data is missing one raised 
burden individual due to a technical error with EndoPAT 2000 (n=8).  
 
 
While keeping focus on the most noteworthy window of RHI as suggested by 
Hamburg and colleagues (2008), there was also a non-significant negative correlation 
between peak RHI (90 seconds post-occlusion) with FRS (p=0.192) and the ACC/AHA 
risk score (p=0.16), shown in Figure 10-A. 66 Likewise, there was a non-significant 
negative correlation when comparing RHI at 120 seconds post-occlusion with FRS 
(p=0.238) and ACC/AHA risk score (p=0.193), as shown in Figure 10-B.   
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Figure 10. (A) Peak reactive hyperemia (90 seconds post-occlusion) correlated with 
Framingham risk score (R2=0.27, p=0.192), and ACC/AHA ASCVD risk score (R2=0.30, 
p=0.16). (B) RHI at 120 seconds post-occlusion correlated with Framingham risk score 
(R2=0.22, p=0.238), and ACC/AHA ASCVD risk score (R2=0.26, p=0.193). 
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DISCUSSION 
 Current data suggests there is an inverse relationship between CVD risk and the 
overall protection obtained through rIpost, supporting our hypothesis. Nine participants 
were split into two groups based on their absolute number of risk factors. The majority of 
the raised burden participants (2 risk factors) completed both sham and rIpost trials, 
while the low burden participants (<2 risk factors) were only able to complete the rIpost 
trial due to limited supplies. Remote Ipost was preformed for three, 5-minute cycles of 
ischemia and reperfusion at the right brachial artery, using a rapid-inflation cuff at 220 
mmHg, immediately following 20 minutes of left arm ischemia. Vascular function was 
measured using EndoPAT 2000, before IR-injury and after sham and rIpost trials.  
Main Findings 
The main significant finding from this study occurs when directly comparing the 
absolute number of risk factors with peak reactive hyperemia at 90 seconds post-
occlusion. The 90-120 second window of reactive hyperemia was deemed the most 
significant by Hamburg and colleagues (2008), where they observed the strongest relation 
between CVD risk factors and digital reactive hyperemic response. 66 Figure 9-A shows 
an inverse relationship between total number of risk factors and peak reactive hyperemia 
(R2=0.53, p=0.04). This strong correlation suggests that those with a raised burden of risk 
factors do indeed experience a weakened hyperemic response when compared to those 
with fewer risk factors. The reactive hyperemic response in this case is directly associated 
with blunted protection from rIpost. This relationship continues through 120 seconds 
post-occlusion, (R2=0.47, p=0.061) which may have likely reached statistical significance 
with a larger sample. Likewise, data shows an inverse relationship between both the 
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Framingham risk score and the ACC/AHA ASCVD risk score and RHI at 90 and 120 
seconds post-occlusion (Figures 10-A and 10-B, p>0.05). This relationship suggests that 
as an individual’s risk of developing cardiovascular disease within the next 10-years 
increases, the favorable vascular response to rIpost may be reduced. Framingham risk and 
ACC/AHA scores are directly impacted by CVD risk (age, blood pressure, total 
cholesterol, HDL-cholesterol, diabetes, and smoking status), therefore, we can make the 
assumption that risk factors are in part responsible for the influence of rIpost on RHI.  
During the rIpost trial, the control group experienced an increase in RHI 
following IR-injury (Figure 5, p>0.05). Although this group only consisted of two 
participants, we still anticipated results indicating a more potent, longer lasting response 
to the postconditioning. On average, participants in the raised burden group experienced a 
slight increase in RHI following IR-injury during both the sham and rIpost protocols 
(Figure 6, p>0.05). We expected to see a decrease in RHI during the sham protocol as no 
conditioning was preformed and IR-injury was induced. Similarly, we noted an 
unexpected difference between the baseline measurements of endothelial function during 
the sham and rIpost protocols (Figure 7). This data only represents a portion of our raised 
burden sample (n=4), however it was expected that baseline values would remain similar 
between the two trials to ensure consistent measurements were achieved. Following IR-
injury, these four raised burden participants showed no difference in RHI between the 
sham and rIpost trials for the first 90 seconds, however the RHI decline during the sham 
trial appeared to be more rapid compared to that in the rIpost trial (Figure 8, p>0.05). 
Data suggests that if the raised burden participants were receiving protection from rIpost, 
it may have had a latent activation occurring after the expected peak reactive hyperemia. 
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Mechanisms of Risk Factors and rIpost in Animal Models 
The main objective of ischemic conditioning is to limit the damage caused from 
IR-injury. Individuals with CVD risk factors are prone to having weakened endothelial 
walls from increased vascular resistance, inflammation, and plaque build-up, overall 
leaving the vascular endothelium compromised and more susceptible to damage. 
Ischemic conditioning is a novel method of preventing damage, or greatly reducing 
damage of IR-injury, and has been studied in the remote form since remote ischemic 
preconditioning was discovered in 1993. 67 There are still many unknowns pertaining to 
the specific mechanisms involved in remote ischemic conditioning, however we know it 
begins with the activation of neural and humoral pathways that promote cell survival 
programs in remote organs/tissues. Researchers have pinpointed two key cell survival 
programs known as the reperfusion injury salvage kinase (RISK) and survivor activating 
factor enhancement (SAFE) pathways. Through the induction of staggered reperfusion, 
ischemic postconditioning is capable of releasing autacoid substances (e.g. adenosine, 
bradykinin, and opioids) that bind to G-protein receptor ligands and activate the RISK 
pathway, while TNF activates SAFE. The activation of these pathways inhibit the 
opening of the mPTP, delay the abrupt restoration of intracellular pH, and activate anti-
apoptotic and anti-necrotic pathways. 15,43 The inhibition of the mPTP is crucial, as its 
activation causes mitochondrial depolarization and the disruption of ATP production that 
leads to cellular necrosis.  
 Much of the current literature pertaining to rIpost has been completed using 
animal models that are either healthy, or exhibit acute, clinically-induced risk factors. 
Zhang and colleagues (2017) studied the effects of rIpost, performed on the bilateral 
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femoral artery, on neuroprotection following cerebral IR-injury in rats. 68 These original 
findings demonstrate that rIpost up-regulated mRNA and protein levels of fibulin-5, a 
protein known for its role in vascular remodeling. Researchers noted a distinct decrease 
in infarct size with the rIpost rats, along with preventing leakage of the blood-brain 
barrier. They propose these mechanisms were triggered by the RISK pathway through the 
activation of the PI3K/Akt intracellular signaling. Similarly, another study pinpointing 
the RISK pathway noted an increased activation of GSK-3 dependent cell survival 
signaling as the mode of protection induced from hepatic rIpost. 69 Researchers exposed 
rats to IR-injury at the site of the coronary artery, while preforming hepatic rIpost at the 
onset of coronary reperfusion. The rIpost remotely increased phosphorylation of cardiac 
GSK-3, which overall reduced tissue damage, prevented apoptosis, and allowed for 
restoration of cardiac function. However, while these two studies may show favorable 
outcomes with rIpost, the caveat is that both were completed using healthy rats. The 
pitfall is that clinicians are still not seeing the desired results when translating these 
models to humans. Ghaffari and colleagues (2017) studied rIpost with participants 
receiving thrombolysis after being admitted to the hospital with STEMI. 70 These 
participants, representing the typical candidate of revascularization surgery, were plagued 
with many risk factors such as hypertension, diabetes, dyslipidemia, smoking, etc. 
Remote Ipost was applied on the arm opposite of that which was used for the delivery of 
the thrombolytic agent, and began at the onset of thrombolysis therapy. Researchers 
noted the rIpost group experienced a greater elevation in ST-segment resolution coupled 
with no significant differences in ischemia and infarct size when compared to the control 
group. Not only was the infarct size not statistically different following rIpost, but the 
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elevated ST-segment resolution suggests this group had experienced comparable damage 
as the control group, proving no perceived cardioprotection – a common trend in data 
when attempting to translate ischemic conditioning to clinical settings.  
Clinical Application of rIpost 
There are many practical applications for rIpost that set it apart from its 
counterparts ischemic pre- and perconditioning. As postconditioning is to be applied at 
the immediate onset of reperfusion, it is much more clinically relevant with its ability to 
be implemented following an ischemic event. This data serves as a preliminary 
standpoint, indicating there may in fact be a link between cardiometabolic risk and the 
efficacy of rIpost. The large majority of current research have studied animal models with 
acute, clinically-induced risk factors such as hypertension, dyslipidemia, and diabetes 
mellitus; however, these models are unable to replicate the damage induced by years of 
living with these risk factors such as those in Ghaffari’s study (2017). 70 
Study Limitations  
While our study was meticulously planned, it had certain limitations we were 
unable to account for. Although not statistically significant, the increase in RHI following 
occlusion during the sham protocol suggests 20 minutes of ischemia followed by 30 
minutes of reperfusion may not have been enough time to elicit injury measurable in the 
microvasculature of the index fingers. We should have noted a distinct decrease in 
vascular function/reactive hyperemia following reperfusion in the sham trial, therefore 
PAT may have been unable to measure IR-injury in the microvasculature of the index 
fingers following our set duration of reperfusion. As for the participants, the available 
budget prevented us from acquiring essential materials, and overall limited the number of 
 
 
46 
participants we were able to recruit. The sample predominantly consisted of males, and 
even though there was no ethnic delimitation set on the study, the sample we were able to 
recruit was primarily Caucasian due to our geographical location of Brookings, SD. The 
study was limited to sedentary individuals only, as the act of exercise works in a similar 
conditioning manner to that we were trying to study. This study aimed to represent the 
typical candidate for clinical rIpost, as many participants (8 of 9) were taking some form 
of medication ranging from birth control to hypertension and dyslipidemia medications, 
which may induce pharmacologic conditioning. It is recommended to control for specific 
medications in the future, as well as metabolic diseases such as diabetes.  
Conclusion 
 This study aimed to determine a relationship between CVD risk factors and the 
perceived vasculoprotection induced from rIpost. Data suggests there is in fact an inverse 
relationship between the two variables, demonstrating that as the absolute number of risk 
factors increase, the reactive hyperemic response following rIpost decreases. A larger 
sample would be required for future studies, however this current data serves as a 
valuable starting point in the link between CVD risk and rIpost.
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Protect Your Heart and Blood Vessels – Participate in a Research Study 
 
Brian.Hemenway@sdstate.edu 
(303) 507-3194 
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(303) 507-3194 
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Who we want: 
 
• Healthy adults 
• 20-79 years old 
• Not taking certain 
medications 
• Non-smoking 
• Not regularly active 
What you get: 
 
• Cholesterol and blood 
pressure screening 
• Fitness and body 
composition assessment 
• State-of-the-art vascular 
health screening 
How long does this 
take? 
 
• Three sessions 
• Flexible scheduling over 
1-2 months 
• Requiring about 8 hours 
of your time 
Where do I do this? 
 
• Vascular Protection 
Laboratory 
• Department of Health & 
Nutritional Sciences 
• On the South Dakota 
State Campus 
 
This study is directed by Dr. Gary Van Guilder of the Vascular Protection Laboratory at South 
Dakota State and has been approved by the SDSU Institutional Review Board #IRB-1507003-EXP 
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APPENDIX B 
 
  
To whom it may concern, 
 
Members of the Vascular Protection Research Laboratory at South Dakota State 
University are currently recruiting research volunteers to participate in a valuable study 
focused on cardiovascular health. We are trying to learn new ways to enable the tissues 
in our body to resist damage caused by a vascular event (e.g., heart attack, stroke, organ 
transplantation).  
 
Without your support to volunteer in this study, we would not be able to learn new and 
effective ways to prevent and treat heart disease – a disease that has been the leading 
cause of death in the United States every year since 1908. As such, I would like to invite 
you to participate in this important study. If you are interested, please call or email Mr. 
Brian Hemenway at the contact information listed at the end of this letter. Mr. 
Hemenway will determine if you meet eligibility requirements and answer any questions 
you may have.  
 
The study will consist of three scheduled sessions based on your availability. In the first 
session, you will complete an assessment of blood pressure, cholesterol and blood sugar 
values, body composition, and a short walking test. In the final two sessions, we will 
measure how well your arteries in your arm function in response to physiological stress. 
We are looking for non-smoking men and women of all ages and ethnicities (>20 yrs) who 
do not regularly exercise. You will be provided all of your health information with a clinical 
explanation as part of the study. 
 
If you are interested, please call, email, or text Mr. Hemenway to determine if you are 
eligible to participate.  
 
Thank you for your interest to improve cardiovascular health by volunteering for this study. 
On behalf of all the members of my research team, we are extremely grateful for your 
participation.  
 
Sincerely, 
 
Gary P. Van Guilder, Ph.D. 
Assistant Professor 
Director, Vascular Protection Research Laboratory 
Department of Health and Nutritional Sciences 
South Dakota State University 
Phone: 715-450-6734 
gary.vanguilder@sdstate.edu 
 
Brian Hemenway | 303-507-3194 | brian.hemenway@sdstate.edu 
Department of Health and  
Nutritional Sciences 
 
Vascular Protection Research 
Laboratory 
 
116 Intramural Building   
South Dakota State University 
Brookings, SD 57007-1497 
Phone: 605-688-4082 
Gary.vanguilder@sdstate.edu 
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APPENDIX C 
 
Participant Informed Consent Form 
Participation in a Research Project 
South Dakota State University 
Brookings, SD 57007 
 
Department of Health and Nutritional Sciences 
Project Director: Dr. Gary P. Van Guilder   Phone No: 605-688-4082 
E-mail: gary.vanguilder@sdstate.edu    Date: 06/01/15 
 
Please read (listen to) the following information:  
 
1. This is an invitation for you, ______________________________, to participate in a 
research project under the direction of Dr. Gary P. Van Guilder, Director of the Human 
Vascular Protection Laboratory in the Department of Health & Nutritional Sciences.  
 
2. The project is entitled:  Influence of Heart Disease Risk Factors on Ischemic 
Conditioning – Experiment 2 
 
3. Ischemic conditioning is a process that helps your blood vessels withstand the 
physiological stress that occurs when blood flow is stopped to a tissue. The purpose of 
the project is to identify how risk factors for heart disease, such as obesity, high 
cholesterol, or aging, affect the ability of ischemic conditioning to protect against this 
stress.  
 
4. If you consent to participate, you will undergo 3 research sessions over the course of 3 
months for a total duration of about 8 hours. Each session is described below. 
Session 1 
 
During the first testing session, we will determine whether you have any cardiometabolic 
risk factors, measure your resting heart rate and blood pressure, body height, weight, waist 
circumference, and percent body fat. You will also undergo a fitness test on a treadmill. 
The time required for session 1 will be ~2 hours. 
 
Measurement of blood fats and sugars: Following an overnight fast of at least 10 hours, 
we will take a small drop of blood from your index finger using a tiny finger prick to 
measure the amount of fats and sugar in your body. The finger prick will take only one 
second to complete. During this test, you may feel a small prick that may be somewhat 
uncomfortable. After we have obtained the drop of blood, we will clean and place a band 
aid on your finger and provide you with something to eat and drink. 
 
Measurement of resting heart rate and blood pressure: Following the finger prick 
described above, you will be rest quietly for 5 minutes until we measure your heart rate 
and blood pressure. Resting heart rate will be measured using a 60 second arterial pulse 
count. To measure your blood pressure, we will place an inflatable cuff around your upper 
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arm. We will inflate the cuff to a high pressure. Then we will release the pressure slowly 
while we listen for the sound of your heartbeat. We will repeat this measurement at least 
twice.   
 
Measurement of body composition: Thereafter, we will measure your height and body 
weight using a digital scale. Abdominal waist circumference will be assessed with a tape 
measured at the smallest part of the abdomen. Percent body fat and muscle mass will be 
estimated by air displacement plethysmography. During this procedure, you will be placed 
in a small enclosed chamber and instructed to sit quietly for 2 minutes. This procedure does 
not require you do anything except sit quietly.  
 
Cardiorespiratory fitness 
 
If you are over the age of 35, you will undergo the ‘Ebbeling sub-maximal walk test’, an 
8-minute brisk treadmill walk to determine your cardiorespiratory fitness. This walking 
test is suitable for low risk, apparently healthy, middle-aged adults.  The first few minutes 
of this test will consist of placing a heart rate monitor and wrist watch on you to measure 
the intensity of the walk. We will then determine a brisk self-selected walking pace that 
equates to 50-75% of your estimated maximum heart rate. The first 4 minutes of the 
walking test will be flat at your self-selected pace. Then, we will increase the ramp of the 
treadmill to 4% grade and you will maintain the same walking speed for 4 more minutes. 
The test will be completed in 8-9 minutes and then we will cool you down for 3 minutes at 
a slow walking speed.  
 
If you are under the age of 35, you will have the choice to undergo a maximum 
cardiorespiratory fitness test or to complete the walk test described above. The research 
team will discuss with you the test that best suits you. The maximum fitness test will 
measure the amount of oxygen your muscles use while you jog at a moderate to vigorous 
intensity on a treadmill to exhaustion. You will jog at self-selected brisk pace during this 
test.  Every 2 minutes, we will increase the incline of the treadmill by 2% until you reach 
your maximum exercise capacity. You will reach your maximum capacity in about 10-12 
minutes. During the exercise test, we will conduct a procedure known as open-circuit 
indirect calorimetry, which will allow us to measure your expired levels of oxygen and 
carbon dioxide, your heart rate, and your breathing rate. You will be equipped with via a 
mouthpiece and nose clip to collect your expired air. At the end of the test, we will reduce 
the speed of the treadmill to a brisk walk and reduce the incline to 0% for 3-5 minutes for 
a cool-down period. The criteria to identify whether you reach maximum capacity will be 
based on your heart rate and the amount of oxygen and carbon dioxide that you breathe out 
through the mouthpiece.  
 
Sessions 2 and 3 
 
On a separate testing day, you will be randomized to participate in either the remote 
preconditioning trial or a control trial first. At least one week after you completed session 
2, you will be scheduled to complete session 3, the other trial. Each of these trials, described 
below, will last about 2-2.5 hours.  
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Each of these trials will consist of four parts over 2-2.5 hours: 
 
Part 1: measurement of blood vessel health 
Part 2: forearm reperfusion injury 
Part 3: remote ischemic postconditioning or control 
Part 4: repeated measurements of blood vessel health 
 
Part 1 - measurement of blood vessel health: One of the main functions of your 
blood vessels is to ensure that all organs and tissues are supplied with adequate 
blood flow to match metabolic demand. The vessel regulates blood flow by dilation 
(increase volume – increase supply) or constriction (decrease volume – decrease 
supply). With each heartbeat, a pulse is produced that increases the volume of blood 
delivered to your limbs. This volume change can be detected to provide an 
indication of blood vessel health. We will measure this volume change using a non-
invasive procedure known as digital pulse arterial tonometry. This test will involve 
the use of a small fingertip cuff that detects small changes in index figure volume 
with each pulse beat. The amplitude of each arterial pulse can be quantified and 
analyzed by an automated, proprietary computer algorithm and tracked over time 
during the experiment. This test will be administered while you lie down in a 
comfortable, quiet room. It consists of three, 5-minute phases:  
 
Phase 1: baseline 
Phase 2: Short-term occlusion of blood flow 
Phase 3: Rapid return of blood flow (hyperemia) 
 
An air-filled finger cuff will be positioned on your index finger of each hand and 
set by a computer to inflate to 10 mmHg below your diastolic blood pressure (about 
70 mmHg). The finger cuff contains sensors that detect changes in finger volume. 
Because the finger cuff contains sensors that detect changes in finger volume, it is 
important that your fingernails be trimmed to obtain the best signal. We will 
provide nail clippers as needed. Following 5 minutes of baseline data acquisition, 
a blood pressure cuff will be inflated on the left upper arm to 220 mmHg for 5 
minutes to occlude blood flow to your left hand. After 5 minutes of arm occlusion, 
the blood pressure cuff will be deflated and measurement of the change in fingertip 
volume will be assessed for 5 minutes. The total duration of this measurement will 
be 15-20 minutes. You will complete this procedure 4 times during sessions 2 and 
again during 3.   
 
Part 2 - forearm reperfusion injury: Immediately after part 2, your left arm will 
undergo reperfusion injury by inflating a high pressure cuff to 220 mmHg for 20 
minutes, followed by 15 minutes of reperfusion. Because arm occlusion is 
sustained for a longer period during this part, you may experience greater 
discomfort and more intense feelings of numbness of the arm, hand and fingers. 
While most subjects do not report any pain, it is somewhat uncomfortable. During 
the 15 min reperfusion phase, a greater rush of blood in the arm will occur and you 
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may feel ‘pins and needles’.  
 
Part 3 - remote ischemic postconditioning or control: Postconditioning your 
muscles has been shown to improve the function of your blood vessels and to 
protect the heart. It can be caused by stopping blood flow to a tissue (e.g. muscle) 
for very short periods of time (i.e., a few minutes) and then letting blood flow back 
into the tissue for an equal amount of time. Stopping blood flow in this manner does 
not damage the tissue. You will undergo postconditioning of your right arm. A 
pressure cuff will be inflated around your right arm to a pressure similar to a blood 
pressure measurement while you rest on a hospital bed. Three, 5 minutes high-
pressure inflations followed by three, 5 minute deflations will occur. We will 
measure your heart rate and blood pressure during the last minute of each 5 minute 
inflation-deflation cycle. The control trial will consist of the same procedure 
described here except the pressure cuff will be inflated to a low pressure to avoid 
stopping blood flow your arm. 
 
Part 4 – repeated measurements of blood vessel health: Following forearm 
injury, we will repeat the measurement of your blood vessel health one additional 
time in the final hour of the procedure. This is the same measurement as described 
above under ‘Part 1’.  
 
5. Participation in this project is voluntary. You have the right to drop out at any time 
without penalty and you have the right not to participate in any aspect of the study. If 
you are a student, your grade for any class will not be affected if you volunteer for this 
project. You will not get extra credit by volunteering for this study. If you have any 
questions, you may contact Dr. Van Guilder at the phone number listed at the end of 
this form. 
 
6. There are minimal risks to you if you volunteer for this project. First, blood pressure 
measurements involve inflating an upper arm cuff to a high pressure for 20 seconds. 
You may experience some mild discomfort during this test. Although obtaining a 
sample of whole blood (one drop, or about 40µl) via a small finger prick is safe and 
confers minimal physical risk, there is a chance that you will experience mild pain for 
a few seconds during the procedure. In addition, the finger prick may cause tiny 
bruising on the skin that should subside in a day. With respect to postconditioning your 
arm, the procedure is quick and poses no more than minimal risk to you. Blood flow to 
your right arm will be stopped for 5 minutes using a high pressure cuff. As a result, you 
will experience tight squeezing of the arm that may be mildly uncomfortable. Although, 
generally painless, you may experience mild numbness for 5 minutes. Lastly, when the 
blood pressure cuff is deflated, you will experience a rush of blood flow through the 
right arm. The skin will redden and feel warm with transient feelings of ‘pins and 
needles’ in the skin as blood flow returns to normal. These feelings should subside 
within 2-3 minutes.  
In contrast, forearm reperfusion injury is induced by occluding blood flow to the left 
arm for 20 min, followed by 15 min of reperfusion. This protocol of prolonged arm 
ischemia followed by reperfusion is a well-established method to show the protective 
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benefits of postconditioning in human subjects. Because arm occlusion is sustained for 
a longer period, you may experience greater discomfort and more intense feelings of 
numbness of the arm, hand and fingers. While most subjects do not report any pain, it 
is somewhat uncomfortable. You may also feel that the arm is cold compared with the 
unaffected arm. Finally, the pressure cuff may cause minor bruising to the tissue of the 
upper arm. Placing the pressure cuff over a shirt sleeve will lessen the chance of 
bruising.  During the 15 min reperfusion phase, a greater rush of blood in the left arm 
will occur. Similar to the blood vessel health test, the skin will redden and feel warm 
with transient feelings of ‘pins and needles’ as blood flow returns to normal. Some 
subjects report mild muscle twitching in the fingers and thumb during this phase. 
 
7. By volunteering for this study, you will receive a state-of-the-art assessment of your 
vascular health and gain insight into the changes that occur in your blood vessels after 
a period of sustained arm occlusion. Moreover, you will be provided your respective 
cardiovascular risk factor information and your personal data regarding body 
composition and cardiorespiratory fitness at the conclusion of the study.  
 
8. You will not be financially compensated by volunteering for the project. There is no 
financial cost to you for volunteering for this project. 
 
9. Your data is strictly confidential. When the data and analysis are presented, you will 
not be linked to the data by your name, title or any other identifying item. To keep your 
identity protected we will assign you a unique alphanumeric code. This code will only 
be available to the research team. The code will link you to the study instead of your 
name. Your information will be kept confidential in a password-protected University 
computer. Copies of data forms will be stored in a locked filing cabinet in the office of 
Dr. Gary Van Guilder. All samples of your blood and DNA will coded using the 
alphanumeric code that we assign to you; they will not be linked to your name, address, 
or any other personal identifying information. All samples will be stored in a secure 
location in the Department of Health & Nutritional Sciences.  
I have read the above and have had my questions answered. I agree to participate in the 
research project. I will receive a copy of this form for my information. 
 
Participant's Signature _________________________________ Date __________ 
 
 
Project Director's Signature _____________________________Date __________ 
 
If you have any questions regarding this study you may contact the Project Director, Dr. 
Gary Van Guilder, using the contact information presented below. If you have questions 
regarding your rights as a participant, you can contact the SDSU Research Compliance 
Coordinator at (605) 688-6975 or SDSU.IRB@sdstate.edu. 
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Project Director: 
Gary P. Van Guilder, Ph.D. 
Assistant Professor 
Department of Health and Nutritional Sciences 
South Dakota State University 
Box 2203, Intramural 116 
Brookings, SD 57007 
Phone: 605-688-4082 
Email: gary.vanguilder@sdstate.edu 
 
This project has been approved by the SDSU Institutional Review Board, Approval No.: 
IRB-1507003-EXP  
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APPENDIX D 
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APPENDIX E 
 
Vascular Protection Research Laboratory 
Department of Health and Nutritional Sciences 
Eligibility Screening Questionnaire 
 
This Eligibility Screening Questionnaire is necessary to help us understand any potential risks 
associated with your eligibility in participating in a research study. All information you provide is 
personal and confidential.  
 
I. GENERAL INFORMATION 
Name  
Address  
City  
State  
Zip code  
Phone (home)  
Phone (work)  
Email  
Age   
Sex   
Hispanic Identity   
Race   
Emergency 
Contact 
 Phone  
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II. MEDICAL DIAGNOSES 
Do you have or have you ever had any of the following conditions? Please check 
yes or no. 
Condition Yes No Condition Yes No 
Heart attack   Pulmonary disease   
Chest pain   Heart valve problems   
Asthma   Heart murmur   
Anemia   Rheumatic fever   
Cardiovascular surgery   Phlebitis   
Currently pregnant   Emboli (blood clot)   
Emphysema or COPD   Coronary artery disease   
Diabetes (type 1 or type 2)   Stroke   
Cancer   Peripheral artery disease   
Raynaud’s disease   Kidney disease   
 
Please list any additional special conditions (e.g., recent injuries or surgeries, and 
muscle or bone pain).  
   
   
 
III. Major Chronic Disease Risk Factors 
 
 
Risk Factor Yes No 
Not 
sure 
Are you a man over the age of 45 or a woman over the age of 55?    
Are you postmenopausal?    
Has your father or brother experienced a heart attack before age 55?    
Has your mother or sister experienced a heart attack before the age of 65?    
Has your doctor ever told you that you might have high blood pressure?    
Is your cholesterol above 200 mg/dl?    
Do you have prediabetes (blood sugar ≥100 mg/dl)?    
Are you physically inactive (less than 30 minutes of physical activity on at 
least 3 days/week)? 
   
Do you currently smoke or have you quit smoking in the last 6 months?    
Are you > 20 pounds overweight?    
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IV. Signs and Symptoms of Chronic Disease 
 
 
Cardiovascular diseases include cardiac, peripheral vascular or cerebrovascular disease 
Pulmonary diseases include chronic obstructive pulmonary disease, asthma, interstitial lung disease, or 
cystic fibrosis 
Metabolic diseases includes Type 1 or 2 Diabetes mellitus, thyroid disorders, renal or liver disease 
 
V. MEDICATIONS 
Please list any medications you are currently taking including prescriptions 
medications and over the counter medications, dietary supplements, vitamins, 
minerals, etc. 
Medication Dose and frequency 
  
  
  
  
  
  
  
 
 
 
Signs/Symptoms  Yes No 
Pain discomfort (or angina equivalent) in the chest, neck, jaw, arms, or other areas 
that may be due to ischemia (decreased blood flow) 
  
Shortness of breath at rest or with mild exertion   
Dizziness or fainting at rest or with mild exertion   
Orthopnea/paroxysmal nocturnal dyspnea (labored breathing at night or while 
sleeping) 
  
Edema (excessive accumulation of tissue fluid usually in the ankles and lower 
legs) 
  
Palpitations or tachycardia (sudden rapid heartbeat)   
Intermittent claudication (lameness due to decreased blood flow)   
Known heart murmur (abnormal heart sound)   
Unusual fatigue   
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VI. SUPPLEMENTS 
Please list any dietary supplements you are currently taking including, but not 
limited to vitamins, minerals, energy drinks, weight loss/weight gain supplements 
etc. 
Dietary supplement Dose and frequency 
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APPENDIX F 
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APPENDIX G 
 
Anthropometric and Hemodynamic Data Sheet 
Vascular Protection Research Laboratory 
South Dakota State University 
 
Subject ID: Tech: Date: 
 
 
Variable Value 
Age, year  
Height, cm  
Weight, kg  
BMI, kg/m2  
Obesity status  
Waist circumference, cm  
Hip circumference, cm  
WHR  
WHR status  
Body fat, %  
Resting heart rate, bpm  
Resting blood pressure 1, mmHg / 
Resting blood pressure 2, mmHg / 
Blood pressure classification  
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APPENDIX H 
 
Ebbeling Sub-Maximal Walk Test 
 
The single stage (8 minutes) treadmill walking test is a submaximal aerobic fitness 
test that estimates VO2max. It is suitable for low risk, apparently healthy, non-
athletic adults 20-59 years of age. The walking pace required throughout the test 
also makes it appropriate for participants who experience problems such as knee 
pain when exercising at a jogging pace. The test can be administered to moderate 
sized groups of participants with low to moderate fitness levels and requires only 
a treadmill and a HR monitor. 
 
Protocol 
1. Calculate 85% of the client’s age-predicted max heart rate and record below. 
2. Calculate 50-70% of his/her age-predicted max heart rate and record below. 
3. Briefly explain the purpose of the test and how it is conducted to the client. 
4. Obtain a stopwatch or timer. Instruct the participant straddle the treadmill.  
5. When ready, instruct the client to warm up for 4 minutes while walking at 0% 
grade and a speed that corresponds to a heart rate between 50-70% of the 
age-predicted max. The recommended walking speed is from 3.4 to 4 mph, 
although these are highly variable.  
6. Measure radial pulse counts the last 15 seconds of each minute. If heart rate 
is not between 50-70% of age-predicted max after the first minute, adjust the 
speed accordingly. 
7. Following the 4-minute warm-up and after you have determined the appropriate 
walking speed, keep the participant at the same speed for an additional 4 
minutes and while setting the grade to 5%.  
8. Record steady-state heart rate from the average of the final 15 sec of the last 
two minutes at the 5% grade. (Note: to achieve steady-state, the heart rate from 
the last two minutes must not differ by more than 5 bpm. If the rate differs by 
more than 5 bpm, extend the test by an additional minute and record the 
steady-state heart rate for the new final two minutes. i.e., minutes 8 and 9). 
9. At the end of the test, instruct the client to cool down at a slow walk and 0% 
grade for 2-5 min. Monitor and record the heart rate every minute. 
10. Enter steady-state heart rate into the equation below to estimate VO2max 
(mL/kg/min). 
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Data Collection Sheet for the Ebbeling Walking Test 
 
Name: Date: 
Resting HR: 
 
bpm 
Resting BP:                                                        mmHg 
Age: yrs 
 Gender M or F 
Body Mass: 
 
kg 85% predicted HRmax: 
 
bpm 
Warm-up HR Training Zone: 
 
50% predicted HRmax = 
 
bpm 
 
70% predicted HRmax = 
 
bpm 
Time 
(min) 
 
Speed 
(mph) 
 
Grade (%) 
HR 
(bp)
m) 
R
P
E 
 
 
 
Warm-up 
1  0   
2  0   
3  0   
4  0   
 
 
 
 
Workload 
5  5   
6  5   
7  5   
8  5   
9
* 
 5   
 
Recovery** 
(reduce walking 
speed and set 
grade to 0%) 
1  0   
2  0   
3  0   
4  0   
5  0   
* 9th minute only required if HR during the 7th and 8th minute has not reached 
steady-state (within 5 bpm) 
 
** An active recovery period of 2-5 minutes should immediately follow this test. 
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Interpretation 
VO2max is estimated using the following equation where: 
 
 speed = mph 
 HR = bpm 
 age = years 
 gender = 1 for males and 0 for females 
 
VO2 max = 15.1 + (21.8 x speed) – (0.327 x HR) – (0.263 x speed x age) + 
(0.00504 x HR x age) + (5.98 x gender) 
 
 
 
 
 
 
EXAMPLE 
Client is a 30-year-old male who walked at 3.6 mph at a grade of 5% with a steady-
state HR of 159 bpm. 
HRmax = 190 bpm; 
50% HRmax = 95 bpm; 
70 % HRmax = 133 bpm: 
 
Estimated VO2max 
= 15.1 + (21.8 x 3.6) - (0.327 x 159) - (0.263 x 3.6 x 30) + 
(0.00504 x 159 x 30) + 5.98 (1) 
= 43.2 mL/kg/min 
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APPENDIX I 
 
Ischemic Postconditioning Protocol 
Vascular Protection Research Laboratory 
 
Subject ID: Tech: Date: Trial: 
 
Phase 
Time 
(min) 
Protocol 
Heart Rate, 
BPM 
Blood 
Pressure, 
mmHg 
Baseline 0 Resting  / 
1 30 min Before rIpost/sham  / 
2 80 min 
30 min after 
reperfusion 
 / 
 
Cuff placement instructions: 
Remote postconditioning cuffs are placed on right arm. Forearm IR-injury cuff 
is placed on left arm.  Place pressure cuffs snugly on the upper arms as high 
as possible.  
Ischemic postconditioning trial: 
Immediately following left arm reperfusion, inflate pressure cuff on right arm to 
220 mmHg to cause ischemia for 5 minutes, followed by 5 minutes of cuff 
deflation – repeat 3 times. Record heart rate and blood pressure before and 
after the postconditioning phase.  
Sham control trial: 
Immediately following left arm reperfusion, inflate pressure cuff on right arm to 
20 mmHg for 5 minutes (simulating mock ischemic occlusions), followed by 5 
minutes of cuff deflation – repeat 3 times. Record heart rate and blood 
pressure before and after the sham phase. 
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